Skip to main content
Top
Published in: Clinical and Experimental Nephrology 1/2015

01-02-2015 | Images in Nephrology

Copper beaten skull in X-linked hypophosphataemic rickets

Authors: Rapur Ram, Vemuri Chaitanya, Vishnubotla Siva Kumar

Published in: Clinical and Experimental Nephrology | Issue 1/2015

Login to get access

Excerpt

Convolutional markings could be normal impressions of the gyri on the inner table of the skull, seen predominantly posteriorly. If they are pronounced over the more anterior parts of the skull, then this is referred to as a copper beaten skull (CBK). Silver beaten skull also refers to the same condition. The CBK appearance is typically associated with craniosynostosis (Fig. 1 and supplementary figure). Consequently, the growing brain exerts a continuous pulsatile pressure on the malleable cranium, producing a gyral pattern evidenced on plain skull radiographs. CBK is a consequence of craniosynostosis and not specific for X-linked hypophosphataemic rickets (XLH). In XLH, the levels fibroblast growth factor (FGF) 23 expressed in kidney are elevated, and there is a cross-binding at the cranial sutures of FGF23 with FGF receptor 2 expressed in osteoblasts, thus accounting for association of craniosynostosis and XLH, and this may explain why CBK is seen in XLH.
Appendix
Available only for authorised users
Metadata
Title
Copper beaten skull in X-linked hypophosphataemic rickets
Authors
Rapur Ram
Vemuri Chaitanya
Vishnubotla Siva Kumar
Publication date
01-02-2015
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 1/2015
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-014-0946-5

Other articles of this Issue 1/2015

Clinical and Experimental Nephrology 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.